{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:12:58Z","timestamp":1762506778760},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2015-1142_s_999_w2aab2b8c39b1b7b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p> Serum human epididymis protein 4 (HE4) has gained relevance as an ovarian cancer (OC) biomarker and new automated methods have replaced the first released manual EIA by tracing results to it. We verified agreement and bias of automated methods vs. EIA as well as possible effects on patients\u2019 management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1142_s_998_w2aab2b8c39b1b7b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p> One hundred and fifteen serum samples were measured by Abbott Architect <jats:italic>i<\/jats:italic>2000, Fujirebio Lumipulse <jats:italic>G<\/jats:italic>1200, Roche Modular E170, and Fujirebio EIA. Passing-Bablok regression was used to compare automated assays to EIA and agreement between methods was estimated by Lin\u2019s concordance correlation coefficient (CCC). The bias vs. EIA was estimated and compared to specifications derived from HE4 biological variation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1142_s_997_w2aab2b8c39b1b7b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p> Median (25th\u201375th percentiles) HE4 concentrations (pmol\/L) were 84.5 (60.1\u2013148.8) for EIA, 82.7 (50.3\u2013153.9) for Abbott, 89.1 (55.2\u2013154.9) for Roche, and 112.2 (67.8\u2013194.2) for Fujirebio. Estimated regressions and agreements (95% confidence interval) were: Abbott=1.01(0.98\u20131.03) EIA\u20134.8(\u20137.5\/\u20132.6), CCC=0.99(0.99\u20131.00); Roche=0.91(0.89\u20130.93) EIA+5.7(4.2\/8.0), CCC=0.98(0.98\u20130.99); Fujirebio=1.20(1.17\u20131.24) EIA+ 2.4(\u20130.6\/4.9), CCC=0.97(0.96\u20130.98). The average bias vs. EIA resulted within the desirable goal for Abbott [\u20133.3% (\u20136.1\/\u20130.5)] and Roche [\u20130.2% (\u20133.0\/2.5)]. However, while for Abbott the bias was constant and acceptable along the measurement concentration range, Roche bias increased up to \u201328% for HE4 values &gt;250 pmol\/L. Lumipulse showed a markedly positive bias [25.3% (21.8\/28.8)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1142_s_996_w2aab2b8c39b1b7b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p> Abbott and Roche assays exhibited a good comparability in the range of HE4 values around the previously recommended 140 pmol\/L cut-off. For patient monitoring, however, the assay used for determining serial HE4 must not be changed as results from different systems in lower and higher concentration ranges can markedly differ.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2015-1142","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T23:40:36Z","timestamp":1459381236000},"page":"1635-1643","source":"Crossref","is-referenced-by-count":26,"title":["Verification of the harmonization of human epididymis protein 4 assays"],"prefix":"10.1515","volume":"54","author":[{"given":"Simona","family":"Ferraro","sequence":"first","affiliation":[{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Borille","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Frusciante","sequence":"additional","affiliation":[{"name":"Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Bassani","sequence":"additional","affiliation":[{"name":"Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Panteghini","sequence":"additional","affiliation":[{"name":"Clinical Pathology Unit, \u2018Luigi Sacco\u2019 University Hospital, Milan, Italy"},{"name":"Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"2023033109501704848_j_cclm-2015-1142_ref_001_w2aab2b8c39b1b7b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Panteghini M. Is serum human epididymis protein 4 ready for prime time? Ann Clin Biochem 2014;51:128\u201336.","DOI":"10.1177\/0004563213500657"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_002_w2aab2b8c39b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 2013;66:273\u201381.","DOI":"10.1136\/jclinpath-2012-201031"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_003_w2aab2b8c39b1b7b1ab2b2b3Aa","unstructured":"International Organization for Standardization (ISO) 17511:2003. In vitro diagnostic medical devices\u2013Measurement of quantities in biological samples\u2013Metrological traceability of values assigned to calibrators and control materials. Geneva: ISO, 2003."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_004_w2aab2b8c39b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combinations algorithm. Clin Chim Acta 2011;412:1447\u201353.","DOI":"10.1016\/j.cca.2011.04.028"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_005_w2aab2b8c39b1b7b1ab2b2b5Aa","unstructured":"Leon AE, Squarcina E, Maggino T, Romagnolo C, Del Pup L, Carvo S, et al. Confronto tra due metodi per la misura nel siero della proteina 4 dell\u2019epididimo umano (HE4) nella diagnosi di carcinoma ovarico. Biochim Clin 2013;37:200\u20137."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_006_w2aab2b8c39b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Sturgeon CM. Common decision limits\u2013The need for harmonised immunoassays. Clin Chim Acta 2014;432:122\u20136.","DOI":"10.1016\/j.cca.2013.11.023"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_007_w2aab2b8c39b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Madsen JS, Nybo M, Magid E, Hilden J, Hornung N, Larsen TB, et al. More studies on outcomes using biochemical diagnostic tests are needed: findings from the Danish Society of Clinical Biochemistry. Clin Chem 2008;54:1254\u20136.","DOI":"10.1373\/clinchem.2007.101808"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_008_w2aab2b8c39b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Hyltoft Petersen P, Klee GG. Influence of analytical bias and imprecision on the number of false positive results using guideline-driven medical decision limits. Clin Chim Acta 2014;430:1\u20138.","DOI":"10.1016\/j.cca.2013.12.014"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_009_w2aab2b8c39b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Schmidt RL, Kordy MA, Genzen JR, Straseski JA, Greene DN, Lehman CM. A mathematical procedure to estimate the impact of a change in method on discordance or misclassification at a decision limit in laboratory method comparison studies. Clin Chim Acta 2015;440:23\u201330.","DOI":"10.1016\/j.cca.2014.10.043"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_010_w2aab2b8c39b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Braga F, Panteghini M. Verification of in vitro medical diagnostics (IVD) metrological traceability: responsibilities and strategies. Clin Chim Acta 2014;432:55\u201361.","DOI":"10.1016\/j.cca.2013.11.022"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_011_w2aab2b8c39b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Braga F, Ferraro S, Mozzi R, Panteghini M. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. Clin Chem Lab Med 2014;52:1625\u201331.","DOI":"10.1515\/cclm-2014-0097"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_012_w2aab2b8c39b1b7b1ab2b2c12Aa","unstructured":"Clinical and Laboratory Standards Institute (CLSI). EP09-A3\u2014Measurement procedure comparison and bias estimation using patient samples; Approved guideline, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2013."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_013_w2aab2b8c39b1b7b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Bablok W, Passing H. Application of statistical procedures in analytical instrument testing. J Automat Chem 1985;7:74\u20139.","DOI":"10.1155\/S1463924685000177"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_014_w2aab2b8c39b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255\u201368.","DOI":"10.2307\/2532051"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_015_w2aab2b8c39b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Fraser CG, Hyltoft Peterson P, Libeer JC, Ricos C. Proposal for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34:8\u201312.","DOI":"10.1177\/000456329703400103"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_016_w2aab2b8c39b1b7b1ab2b2c16Aa","unstructured":"www.r-project.org. Accessed July 2015."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_017_w2aab2b8c39b1b7b1ab2b2c17Aa","unstructured":"National Collaborating Centre for Cancer (UK). National Institute for Health and Clinical Excellence (NICE): Guidance. Ovarian cancer: the recognition and initial management of ovarian cancer. Cardiff, UK: National Collaborating Centre for Cancer, 2011."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_018_w2aab2b8c39b1b7b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem 1998;44:1417\u201322.","DOI":"10.1093\/clinchem\/44.7.1417"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_019_w2aab2b8c39b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006;125:921\u20137.","DOI":"10.1309\/NBA312W0LANRXYH9"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_020_w2aab2b8c39b1b7b1ab2b2c20Aa","unstructured":"Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer). National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed January 2016."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_021_w2aab2b8c39b1b7b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European federation of clinical chemistry and laboratory medicine. Clin Chem Lab Med 2015;53:833\u20135.","DOI":"10.1515\/cclm-2015-0067"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_022_w2aab2b8c39b1b7b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Panteghini M. Implementation of standardization in clinical practice: not always an easy task. Clin Chem Lab Med 2012;50:1237\u201341.","DOI":"10.1515\/cclm.2011.791"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_023_w2aab2b8c39b1b7b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Panteghini M. Traceability as a unique tool to improve standardization in laboratory medicine. Clin Biochem 2009;42:236\u201340.","DOI":"10.1016\/j.clinbiochem.2008.09.098"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_024_w2aab2b8c39b1b7b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Schimmel H, Zegers I, Emons H. Standardization of protein biomarker measurements: is it feasible? Scand J Clin Lab Investig 2010;70(Suppl 242):27\u201333.","DOI":"10.3109\/00365513.2010.493362"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_025_w2aab2b8c39b1b7b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Wei TQ, Zheng YF, Dubowy M, Sharma M. Sandwich assay for tacrolimus using 2 antitacrolimus antibodies. Clin Chem 2014;60:621\u201330.","DOI":"10.1373\/clinchem.2013.214023"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_026_w2aab2b8c39b1b7b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE-4 (WFDC-2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768\u201373.","DOI":"10.1038\/sj.onc.1205363"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_027_w2aab2b8c39b1b7b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci 2013;14:22655\u201377.","DOI":"10.3390\/ijms141122655"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_028_w2aab2b8c39b1b7b1ab2b2c28Aa","unstructured":"Schiumarini D, Ferraro S, Panteghini M. Biochemical and functional characteristics of human epididymis protein 4 (HE4). Biochim Clin 2014;38:368\u201373."},{"key":"2023033109501704848_j_cclm-2015-1142_ref_029_w2aab2b8c39b1b7b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Chhikara N, Saraswat M, Tomar AK, Dey S, Singh S, Yadav S. Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One 2012;7:e47672.","DOI":"10.1371\/journal.pone.0047672"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_030_w2aab2b8c39b1b7b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Ace CI, Okulicz WC. Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod Biol Endocrinol 2004;2:54.","DOI":"10.1186\/1477-7827-2-54"},{"key":"2023033109501704848_j_cclm-2015-1142_ref_031_w2aab2b8c39b1b7b1ab2b2c31Aa","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html: Accessed February 2016."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2016.54.issue-10\/cclm-2015-1142\/cclm-2015-1142.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1142\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:06:07Z","timestamp":1680257167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1142\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,5,11]]},"published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1515\/cclm-2015-1142"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1142","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}